Suspended

SAMHY2Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Blood samples will be collected at different times.

Other
Who is being recruted

Leiomyosarcoma+3

+ Neoplasms

+ Neoplasms by Histologic Type

Over 18 Years
+12 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Other Study

Interventional
Study Start: January 2023
See protocol details

Summary

Principal SponsorInstitut Claudius Regaud
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 13, 2023

Actual date on which the first participant was enrolled.

Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood and the evolution of this rate over time. The study will be conducted on a population of patients with leiomyosarcoma and treated in the context of routine care. 20 patients will be included: * 10 patients with localized disease. * 10 patients with metastatic disease. For each included patient, blood samples will be collected during baseline visit and up to 24 months after inclusion.

Official TitleCirculating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2
NCT05427461
Principal SponsorInstitut Claudius Regaud
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

20 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Other Study

Some studies explore topics that don't fall into a specific category. These might include innovative research, new technologies, or emerging healthcare areas.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

LeiomyosarcomaNeoplasmsNeoplasms by Histologic TypeNeoplasms, Muscle TissueSarcomaNeoplasms, Connective and Soft Tissue

Criteria

7 inclusion criteria required to participate
Patient with leiomyosarcoma.
Diagnosis of sarcoma histologically confirmed by the RRePS network (Réseau de Référence en Pathologie des Sarcomes et des Viscères)
Localized or metastatic disease
Newly diagnosed patient who has not yet initiated specific treatment for sarcoma
Show More Criteria
5 exclusion criteria prevent from participating
Diagnosis of any other histological subtype of soft tissue sarcoma
Associated pathology(ies) that may interfere with the study procedure
Pregnant or breastfeeding woman
Any psychological, family, geographical or sociological condition that does not allow for compliance with the medical follow-up and/or procedures provided for in the study protocol.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Institut Universitaire du Cancer Toulouse - Oncopole

Toulouse, FranceOpen Institut Universitaire du Cancer Toulouse - Oncopole in Google Maps
SuspendedOne Study Center